Filana Therapeutics, Inc. FLNA
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 0.75% | 80.55% | 55.86% | 54.56% | 61.32% |
| Total Depreciation and Amortization | 60.31% | 11.93% | 10.45% | 41.15% | -49.42% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -21.04% | -11.13% | -22.12% | -6.44% | -21.50% |
| Change in Net Operating Assets | 1,684.91% | -98.74% | -143.17% | 92.56% | -98.60% |
| Cash from Operations | 2.04% | 22.07% | 21.68% | 84.09% | 66.00% |
| Capital Expenditure | 61.25% | -- | -- | -778.95% | -370.59% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 61.25% | -- | -- | -778.95% | -370.59% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -156.67% | -135.84% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 29.52% | 21.33% | 20.60% | 82.49% | 65.59% |